Cellectis S.A. (CLLS) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Cellectis S.A. (CLLS) over the past year, losing 24.0% versus a loss of 69.8%. Over five years, CLLS leads with a -88.4% price change compared with -99.9% for HURA. Cellectis S.A. is the larger company by market cap ($126.9 million vs $124.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLLS | HURA |
|---|---|---|
| Share price | $1.26 | $1.96 |
| Market cap | $126.92M | $124.90M |
| 1-day change | +0.80% | +1.55% |
| YTD return | -73.97% | +158.92% |
| 1-year return | -69.78% | -24.03% |
| 5-year return | -88.37% | -99.87% |
| EPS (TTM) | $-0.64 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $5.48 | $3.43 |
| 52-week low | $1.22 | $0.41 |
| Distance from 52-week high | -77.01% | -42.86% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +323.02% | +310.20% |
| Average volume | 80.14K | 245.98K |
| Shares outstanding | 72.73M | 63.73M |
| Employees | 224 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed CLLS by 45.8 percentage points over the past year.
About Cellectis S.A.
CLLS stock →Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL).
Health Care · Biotechnology: Pharmaceutical Preparations · 224 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CLLS vs HURA FAQ
Which is bigger, Cellectis S.A. or TuHURA Biosciences?
Cellectis S.A. (CLLS) is larger, with a market capitalization of $126.92M compared with $124.90M for TuHURA Biosciences (HURA).
Which stock has performed better over the past year, CLLS or HURA?
HURA returned -24.03% over the past 12 months, compared with -69.78% for CLLS (price return, excluding dividends). Past performance does not predict future results.
Are Cellectis S.A. and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.